162 related articles for article (PubMed ID: 20116902)
1. Discovery of new cholesteryl ester transfer protein inhibitors via ligand-based pharmacophore modeling and QSAR analysis followed by synthetic exploration.
Abu Khalaf R; Abu Sheikha G; Bustanji Y; Taha MO
Eur J Med Chem; 2010 Apr; 45(4):1598-617. PubMed ID: 20116902
[TBL] [Abstract][Full Text] [Related]
2. Discovery of new renin inhibitory leads via sequential pharmacophore modeling, QSAR analysis, in silico screening and in vitro evaluation.
Al-Nadaf AH; Taha MO
J Mol Graph Model; 2011 Apr; 29(6):843-64. PubMed ID: 21376648
[TBL] [Abstract][Full Text] [Related]
3. Discovery of new MurF inhibitors via pharmacophore modeling and QSAR analysis followed by in-silico screening.
Taha MO; Atallah N; Al-Bakri AG; Paradis-Bleau C; Zalloum H; Younis KS; Levesque RC
Bioorg Med Chem; 2008 Feb; 16(3):1218-35. PubMed ID: 17988876
[TBL] [Abstract][Full Text] [Related]
4. Elaborate ligand-based modeling reveals new nanomolar heat shock protein 90α inhibitors.
Al-Sha'er MA; Taha MO
J Chem Inf Model; 2010 Sep; 50(9):1706-23. PubMed ID: 20831219
[TBL] [Abstract][Full Text] [Related]
5. Elaborate ligand-based modeling and subsequent synthetic exploration unveil new nanomolar Ca2+/calmodulin-dependent protein kinase II inhibitory leads.
Shahin R; Taha MO
Bioorg Med Chem; 2012 Jan; 20(1):377-400. PubMed ID: 22112539
[TBL] [Abstract][Full Text] [Related]
6. Discovery of new β-D-galactosidase inhibitors via pharmacophore modeling and QSAR analysis followed by in silico screening.
Abdula AM; Khalaf RA; Mubarak MS; Taha MO
J Comput Chem; 2011 Feb; 32(3):463-82. PubMed ID: 20730780
[TBL] [Abstract][Full Text] [Related]
7. Combining ligand-based pharmacophore modeling, quantitative structure-activity relationship analysis and in silico screening for the discovery of new potent hormone sensitive lipase inhibitors.
Taha MO; Dahabiyeh LA; Bustanji Y; Zalloum H; Saleh S
J Med Chem; 2008 Oct; 51(20):6478-94. PubMed ID: 18808096
[TBL] [Abstract][Full Text] [Related]
8. Pharmacophore and QSAR modeling of estrogen receptor beta ligands and subsequent validation and in silico search for new hits.
Taha MO; Tarairah M; Zalloum H; Abu-Sheikha G
J Mol Graph Model; 2010 Jan; 28(5):383-400. PubMed ID: 19850503
[TBL] [Abstract][Full Text] [Related]
9. Discovery of DPP IV inhibitors by pharmacophore modeling and QSAR analysis followed by in silico screening.
Al-Masri IM; Mohammad MK; Taha MO
ChemMedChem; 2008 Nov; 3(11):1763-79. PubMed ID: 18989859
[TBL] [Abstract][Full Text] [Related]
10. Discovery of new antifungal leads via pharmacophore modeling and QSAR analysis of fungal N-myristoyl transferase inhibitors followed by in silico screening.
Taha MO; Qandil AM; Al-Haraznah T; Khalaf RA; Zalloum H; Al-Bakri AG
Chem Biol Drug Des; 2011 Sep; 78(3):391-407. PubMed ID: 21679375
[TBL] [Abstract][Full Text] [Related]
11. Elaborate ligand-based pharmacophore exploration and QSAR analysis guide the synthesis of novel pyridinium-based potent beta-secretase inhibitory leads.
Al-Nadaf A; Abu Sheikha G; Taha MO
Bioorg Med Chem; 2010 May; 18(9):3088-115. PubMed ID: 20378363
[TBL] [Abstract][Full Text] [Related]
12. Discovery of novel CDK1 inhibitors by combining pharmacophore modeling, QSAR analysis and in silico screening followed by in vitro bioassay.
Al-Sha'er MA; Taha MO
Eur J Med Chem; 2010 Sep; 45(9):4316-30. PubMed ID: 20638755
[TBL] [Abstract][Full Text] [Related]
13. Pharmacophore modeling, quantitative structure-activity relationship analysis, and shape-complemented in silico screening allow access to novel influenza neuraminidase inhibitors.
Abu Hammad AM; Taha MO
J Chem Inf Model; 2009 Apr; 49(4):978-96. PubMed ID: 19341295
[TBL] [Abstract][Full Text] [Related]
14. Extensive ligand-based modeling and in silico screening reveal nanomolar inducible nitric oxide synthase (iNOS) inhibitors.
Suaifan GA; Shehadehh M; Al-Ijel H; Taha MO
J Mol Graph Model; 2012 Jul; 37():1-26. PubMed ID: 22609742
[TBL] [Abstract][Full Text] [Related]
15. 2D Quantitative structure-activity relationship studies on a series of cholesteryl ester transfer protein inhibitors.
Castilho MS; Guido RV; Andricopulo AD
Bioorg Med Chem; 2007 Sep; 15(18):6242-52. PubMed ID: 17604633
[TBL] [Abstract][Full Text] [Related]
16. Discovery of new nanomolar peroxisome proliferator-activated receptor γ activators via elaborate ligand-based modeling.
Al-Najjar BO; Wahab HA; Tengku Muhammad TS; Shu-Chien AC; Ahmad Noruddin NA; Taha MO
Eur J Med Chem; 2011 Jun; 46(6):2513-29. PubMed ID: 21482446
[TBL] [Abstract][Full Text] [Related]
17. Discovery of new potent human protein tyrosine phosphatase inhibitors via pharmacophore and QSAR analysis followed by in silico screening.
Taha MO; Bustanji Y; Al-Bakri AG; Yousef AM; Zalloum WA; Al-Masri IM; Atallah N
J Mol Graph Model; 2007 Mar; 25(6):870-84. PubMed ID: 17035054
[TBL] [Abstract][Full Text] [Related]
18. Ligand-based modelling followed by synthetic exploration unveil novel glycogen phosphorylase inhibitory leads.
Habash M; Taha MO
Bioorg Med Chem; 2011 Aug; 19(16):4746-71. PubMed ID: 21788139
[TBL] [Abstract][Full Text] [Related]
19. Elaborate ligand-based modeling coupled with multiple linear regression and k nearest neighbor QSAR analyses unveiled new nanomolar mTOR inhibitors.
Khanfar MA; Taha MO
J Chem Inf Model; 2013 Oct; 53(10):2587-612. PubMed ID: 24050502
[TBL] [Abstract][Full Text] [Related]
20. 2D and 3D QSAR models for identifying diphenylpyridylethanamine based inhibitors against cholesteryl ester transfer protein.
Chen M; Yang X; Lai X; Gao Y
Bioorg Med Chem Lett; 2015 Oct; 25(20):4487-95. PubMed ID: 26346366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]